Vasostrict is a drug owned by Endo Operations Ltd. It is protected by 15 US drug patents filed from 2016 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2035. Details of Vasostrict's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9375478 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US10010575 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9981006 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9974827 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9968649 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9962422 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9925234 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9925233 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9744239 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9744209 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9687526 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US12186362 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9919026 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9750785 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
| US9937223 | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vasostrict's patents.
Latest Legal Activities on Vasostrict's Patents
Given below is the list of recent legal activities going on the following patents of Vasostrict.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2023 | US9375478 |
| Email Notification Critical | 28 May, 2022 | US9925234 |
| Change in Power of Attorney (May Include Associate POA) Critical | 27 May, 2022 | US9925234 |
| Correspondence Address Change Critical | 26 May, 2022 | US9925234 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Dec, 2021 | US10010575 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9968649 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9974827 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9981006 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Oct, 2021 | US9962422 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Sep, 2021 | US9937223 |
US patents provide insights into the exclusivity only within the United States, but Vasostrict is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vasostrict's family patents as well as insights into ongoing legal events on those patents.
Vasostrict's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vasostrict's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 30, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vasostrict Generic API suppliers:
Vasopressin is the generic name for the brand Vasostrict. 8 different companies have already filed for the generic of Vasostrict, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vasostrict's generic
How can I launch a generic of Vasostrict before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Vasostrict's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vasostrict's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Vasostrict -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 units/mL, 1 mL | 23 Mar, 2018 | 1 | 15 Dec, 2021 | 30 Jan, 2035 | Non-Forfeiture Deferred |
| 200 units/10 mL | 29 Jun, 2018 | 1 | 30 Jan, 2035 | Non-Forfeiture | |
| 20 units/100 mL | 20 Dec, 2022 | 1 | 30 Jan, 2035 | ||
| 40 units/100 mL and 60 units/100 mL | 28 Feb, 2022 | 1 | 30 Jan, 2035 |
About Vasostrict
Vasostrict is a drug owned by Endo Operations Ltd. It is used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict uses Vasopressin as an active ingredient. Vasostrict was launched by Endo Operations in 2014.
Approval Date:
Vasostrict was approved by FDA for market use on 17 April, 2014.
Active Ingredient:
Vasostrict uses Vasopressin as the active ingredient. Check out other Drugs and Companies using Vasopressin ingredient
Treatment:
Vasostrict is used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Dosage:
Vasostrict is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200UNITS/10ML (20UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 20UNITS/100ML (0.2UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 50UNITS/50ML (1UNITS/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 20UNITS/ML (20UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 40UNITS/100ML (0.4UNITS/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 60UNITS/100ML (0.6UNITS/ML) | SOLUTION | Discontinued | INTRAVENOUS |